SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-06-17
👔
enGene Therapeutics Inc.
@ENGN_InsiderForm 4 Filing: Astley-Sparke Philip Acquires (Grant) shares of $ENGN
STOCK AWARD / GRANT
⚡ MATERIALITY: 1/10
corporate issuer
enGene Therapeutics Inc.
Ticker: $ENGN
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-06-16
Shares: 31,000
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Astley-Sparke Philip, holds the title of Director at enGene Therapeutics Inc..
On 2026-06-16, the insider transacted 31,000 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Astley-Sparke Philip (Director) was granted $0 of $ENGN
Post-Transaction Position: 31,000 shares
SEC Accession No: 0000929638-26-002263 (CIK: 1376491)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.